BioSpace News Archive

Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors.

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the resignation of Elizabeth (Betsy) Nabel, M.D., from Moderna’s Board of Directors effective today, July 30.

Select Medical Holdings Corporation (“Select Medical,” “we,” “us,” or “our”) (NYSE: SEM) today announced results for its second quarter ended June 30, 2020.

Endo International plc (NASDAQ: ENDP) today announced that it has changed the time of its previously announced conference call in an attempt to reduce conflicts with other earnings calls.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $24 million investment from the U.S. Department of Defense in collaboration with the U.S. Department of Health and Human Services to support the scale up of U.S. manufacturing capabilities for BD Veritor™ Solution for Rapid Detection of SARS-CoV-2 (see demo here).

BioLife Solutions , Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced that the Company’s second quarter 2020 financial results will be released after market close on Thursday, August 6th, 2020 , and

Since July 24, there have been 55 additional illnesses in Canada reported in the ongoing investigation.

The Quick Group has just launched another episode of their QuickConversations podcast, designed to help the pharma, biotech and life science community manage their global supply chain, and keep their critical products and patients safe–utilizing best practices and proven logistics solutions.

Researchers at the University of California, San Francisco (UCSF) and healthcare technology company InsightRX demonstrated that a second-generation Bayesian pharmacokinetic (PK) model enabled highly accurate and repeatable target attainment for busulfan, a conditioning agent typically used in hematopoietic cell transplants (HCTs).

Millstone Medical Outsourcing is pleased to announce the completion of construction on its new Fall River, Massachusetts headquarters facility expansion.